Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Pancreatic Neoplasms 35Carcinoma, Non-Small-Cell Lung 27Breast Neoplasms 15Lung Neoplasms 13Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Neoplasms 10Colorectal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Head and Neck Neoplasms 4Carcinoma, Pancreatic Ductal 4Stomach Neoplasms 3Neoplasms by Site 3Gastrointestinal Neoplasms 3Carcinoma 3Adenocarcinoma 3Vaccinia 2Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms by Histologic Type 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Colonic Neoplasms 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thymoma 1

Interventions

Bevacizumab 39Paclitaxel 35pembrolizumab 27Carboplatin 27Specimen Handling 21olaparib 19Magnetic Resonance Spectroscopy 19Gemcitabine 19liposomal doxorubicin 17Cyclophosphamide 16niraparib 13fludarabine 12Topotecan 12Cisplatin 12Biopsy 12Taxes 9Nivolumab 8Immunoglobulin G 8Fulvestrant 8Doxorubicin 8Disulfides 8Surveys and Questionnaires 7palbociclib 6aldesleukin 6Oxaliplatin 6Letrozole 5Fluorouracil 5trastuzumab deruxtecan 4oregovomab 4mirvetuximab soravtansine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × 130-nm albumin-bound paclitaxel × 90 days × Clear all
NCT06906341 2026-04-14

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Corcept Therapeutics

Phase 2 Recruiting
270 enrolled
Gynecologic

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡